AstraZeneca strikes broad alliance for Amgen's clinical-stage inflammation portfolio

Amgen will get $50 million upfront from AstraZeneca under a collaboration agreement to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, which will allow the US biotechnology company to refocus some of its resources on earlier stage programmes.